產品描述: | MK-8776 (SCH 900776)是一種選擇性Chk1抑制劑,無細胞試驗中IC50為3 nM,比作用于Chk2選擇性高500倍。Phase 2 |
靶點: |
Chk1(Cell-free assay):3 nM; CDK2(Cell-free assay):0.16 μM;Chk;?CDK |
體外研究: |
SCH 900776是Chk2和CDK2的低效抑制劑,IC50分別為1.5 μM 和 0.16 μM。SCH 900776對細胞色素P450人肝微粒體亞型1A2,2C9,2C19,2D6,和3A4沒有顯著的抑制作用。羥基脲下暴露24小時后,SCH 900776誘導DNA復制能力劑量依賴性損失。SCH 900776增強γ-H2AX對羥基脲,5-氟尿嘧啶,和阿糖孢苷的響應。與抗代謝物結合,SCH 900776在2小時內誘導γ-H2AX的累積,表明復制叉瓦解,并且雙鏈DNA斷裂。此外,SCH 900776以劑量依賴的方式抑制Chk1 pS296自磷酸化的積累。增殖的WS1細胞暴露于SCH 900776,與Chk1 pS345快速的,劑量依賴性聚集相關,表明正常細胞的循環群誘導Chk1 pS345在暴露于SCH 900776后,是一部分無效循環,這也許通過AT-家族激酶和DNA-PK驅動 |
體內研究: |
相對于gemcitabine或SCH 900776單獨給藥,Gemcitabine給藥30分鐘后,4 mg/kg SCH 900776足以誘導γ-H2AX生物標志物,而8 mg/kg增強腫瘤藥效動力學和退化響應。遞增劑量的SCH 900776 (16 mg/kg和32 mg/kg)誘導腫瘤響應持續改進。重要的是,在BALB/c 小鼠體內,SCH 900776的劑量與強的生物標志物活化相關,而提高的腫瘤響應與gemcitabine對血液學指標增強的毒性無關. |
細胞實驗: |
Cell lines: mESCs Concentrations: 10 μM Incubation Time: 1 h Method: Cells were treated with inhibitors or vehicle for 1 hour |
動物實驗: |
Animal Models: 皮下注射A2780 或 MiaPaCa2細胞的額雌性裸鼠 Dosages: ~50 mg/kg Administration: 腹腔內注射 |
參考文獻: |
1. Guzi TJ, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther, 2011, 10(4), 591-602. 2. Montano R, et al. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther, 2012, 11(2), 427-438. 3. Schenk EL, et al. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res, 2012, 18(19), 5364-5373. 4. Grow EJ, et al. p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models. Nat Genet. 2021 Aug;53(8):1207-1220. |
溶解性: |
Soluble in DMSO |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.658 ml |
13.289 ml |
26.578 ml |
5 mM |
0.532 ml |
2.658 ml |
5.316 ml |
10 mM |
0.266 ml |
1.329 ml |
2.658 ml |
50 mM |
0.053 ml |
0.266 ml |
0.532 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |